Department of Radiation Oncology, Willis-Knighton Cancer Center, Shreveport, Louisiana, USA.
J Appl Clin Med Phys. 2024 Jun;25(6):e14278. doi: 10.1002/acm2.14278. Epub 2024 Jan 17.
Linear accelerator-based stereotactic radiosurgery (SRS) has become a mainstay for simultaneous management of multiple intracranial targets. Recent improvements in treatment planning systems (TPS) have enabled treatment of multiple brain metastases using dynamic conformal arcs (DCA) and a single treatment isocenter. However, as the volume of healthy tissue receiving at least 12 Gy (V12) is linked to the probability of developing radionecrosis, balancing target coverage while minimizing V12 is a critical factor affecting SRS plan quality. Current TPS allow users to adjust various parameters influencing plan optimization. The purpose of this work is to quantify the effect of negative margins on V12 for cranial SRS plans managing multiple brain metastases.
Using the Brainlab Elements v3.0 TPS (Brainlab, Munich, Germany), we calculated V10, V12, V15, monitor units, and conformity index for seventeen SRS plans treating 2-10 metastases on our Elekta Versa HD (Elekta, Stockholm, Sweden) linear accelerator. We compared plans optimized using 70%-90% prescription isodose lines (IDL) in 5% increments.
Irrespective of the number of treated metastases, optimization at a lower prescription IDL reduced V10, V12, and V15 and increased MU compared to the 90% IDL (p < 0.01). However, comparing the 70% and 75% IDL optimizations, there was little difference in tissue sparing. The conformity index showed no consistent trends at different IDLs due to a significant spread in case data.
For our plans treating up to 10 metastases, diminishing returns for tissue sparing at IDLs below 80% paired with increasing treatment MU and dosimetric hot spot made optimization at lower IDLs less favorable. In our clinic, after consulting with a physician, it was determined that optimization at the 80% IDL achieved the best balance of V12, treatment MU, and maximum dose. Clinics implementing LINAC-based SRS programs may consider using similar evaluations to develop their own clinical protocols.
基于直线加速器的立体定向放射外科(SRS)已成为同时管理多个颅内靶区的主要方法。最近,治疗计划系统(TPS)的改进使得使用动态适形弧(DCA)和单个治疗等中心点可以治疗多个脑转移瘤。然而,由于至少 12 Gy (V12)的健康组织体积与发生放射性坏死的概率有关,因此在目标覆盖的同时最小化 V12 是影响 SRS 计划质量的关键因素。目前的 TPS 允许用户调整影响计划优化的各种参数。本研究的目的是量化颅 SRS 计划中负边缘对多个脑转移瘤 V12 的影响。
使用 Brainlab Elements v3.0 TPS(德国慕尼黑的 Brainlab),我们计算了在 Elekta Versa HD(瑞典斯德哥尔摩的 Elekta)直线加速器上治疗 2-10 个转移瘤的 17 个 SRS 计划的 V10、V12、V15、MU 和适形指数。我们比较了以 70%-90%处方等剂量线(IDL)优化的计划,递增 5%。
无论治疗的转移瘤数量如何,与 90% IDL 相比,使用较低处方 IDL 进行优化会降低 V10、V12 和 V15,并增加 MU(p<0.01)。然而,比较 70%和 75% IDL 的优化结果,在组织保存方面几乎没有差异。由于病例数据的显著差异,适形指数在不同 IDL 下没有一致的趋势。
对于我们治疗不超过 10 个转移瘤的计划,在 IDL 低于 80%时,组织保护的回报递减,同时增加治疗 MU 和剂量热点,使得在较低 IDL 下进行优化变得不利。在我们的诊所,与医生协商后,确定在 80% IDL 下进行优化可以在 V12、治疗 MU 和最大剂量之间取得最佳平衡。实施基于 LINAC 的 SRS 计划的诊所可以考虑使用类似的评估来制定自己的临床方案。